Floatz logo

Enavermotide

Pancreatic Cancer

Samsung Pharmaceutical Co., Ltd.vaccinePhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
59/ 100

Competitive context

382 Active assets in the Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Irinotecan
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Enavermotide is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative ·
60 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →